Overview
Registration
Case Submission
Faculty
Agenda
View Archive

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bayer; Secura Bio, Inc.; and TG Therapeutics, Inc.

Virtual Hot Seat™: Experts Face Key Questions to Maximize the Use of PI3K Inhibitors Across Hematologic Malignancies

Virtual Hot Seat™: Experts Face Key Questions to Maximize the Use of PI3K Inhibitors Across Hematologic Malignancies


December 2, 2021
7:00 PM to 8:30 PM ET
Live, Interactive Webcast!

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bayer; Secura Bio, Inc.; and TG Therapeutics, Inc.

Overview

Over the past several years, several PI3K inhibitors have been approved or are under investigation for the treatment of patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL) and B-cell lymphomas. Updates from clinical trials have shown the impact of PI3K inhibitors on patient outcomes, and clinicians need to know how to incorporate these agents into patient care in their every-day practice.

This Virtual Hot Seat™ is an interactive, game-style, live webcast designed to help clinicians to assess the wealth of emerging data on using PI3K inhibitors to treat hematologic malignancies, choosing appropriate treatment based upon patient and disease characteristics, and applying novel management strategies to their practices to improve patient care across the disease continuum.

Participants will be able to select which expert from the panel who will face the “hot seat” and answer each of the series of challenging, clinically relevant questions. This highly engaging format will provide a unique opportunity for oncologists and other healthcare professionals to learn from and interact with leading experts, increase their clinical knowledge, apply new data to practice, and, ultimately, improve patient outcomes.

 

PER®’s Virtual Hot Seat™: Who will face the fire?

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology healthcare professionals. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with PI3K inhibitors are also invited to attend.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss mechanistic rationale supporting the role of PI3K inhibition in the management of hematologic malignancies, such as CLL, lymphomas
  • Review the evidence from recent and key clinical trials highlighting the role of PI3K inhibitors in the treatment of patients with hematologic malignancies
  • Evaluate potential implications of emerging data as well as planned/ongoing trials evaluating current and investigational PI3K inhibitors in the management of patients with hematologic malignancies
  • Implement strategies to personalize and optimize treatment with PI3K inhibition in hematologic malignancies, including early recognition, proactive mitigation, as well as effective management of treatment-related toxicities

Benefits of Attending

  • Participate in the action and steer the course of the webcast by selecting the faculty member you want to see in the hot seat to answer each of the challenging questions
  • Experience the intensity of rapid-fire questions asked and concise responses and follow-up discussion offered by the expert panel
  • Receive the latest recent clinical data concerning use of PI3K inhibitors to treat hematologic malignancies
  • Hear experts discuss the impact of PI3K inhibitors on the treatment of patients with CLL or B-cell lymphoma
  • Learn about factors to consider when selecting a PI3K inhibitor

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities
 

Chair

Javier Pinilla-Ibarz, MD, PhD
Javier Pinilla-Ibarz, MD, PhD
Senior Member
Director of Immunotherapy
Department of Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Professor, Department of Oncologic Sciences
Morsani College of Medicine
University of South Florida
Tampa, FL

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By